argus

Caplin Point Laboratories Ltd.

NSE: CAPLIPOINTINE475E0102620,657 Cr

Timeline

Time (IST)TypeMEventSrc
05 Feb, 01:21 pmCaplin Point Laboratories Ltd - 524742 - Financial Results For The Quarter Ended December 31, 2025bse
05 Feb, 01:14 pmCaplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.nse
05 Feb, 01:08 pmCaplin Point Laboratories Ltd - 524742 - Board Meeting Outcome for Outcome Of Board Meetingbse
03 Feb, 03:24 pmCaplin Point Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.nse
03 Feb, 03:23 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Change in Managementbse
27 Jan, 04:03 pmThe Company has informed the Exchange regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the ANDA Methylprednisolone Acetate Injectable Suspension USP.nse
27 Jan, 03:28 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
27 Jan, 11:37 amCaplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025.bse
01 Jan, 11:34 amCaplin Point Laboratories Limited has informed the Exchange regarding 'Intimation of Press Release on Acquisition of ANDAs'.nse
12 Dec, 05:39 pmCaplin Point Laboratories Limited has informed the Exchange regarding the successful completion of INVIMA - Colombia inspection of the injectables facility at Puducherry.nse
09 Dec, 01:47 pmCaplin Point Laboratories Limited has informed the Exchange regarding 'Press Release' on its Subsidiary, Caplin Steriles Limited, receiving USFDA approval for its Abbreviated New Drug Application (ANDA) Linezolid Injection 600mg/300mL (2mg/mL) Single-dose Infusion Bagsnse
08 Dec, 03:36 pmCaplin Point Laboratories Ltd - 524742 - Intimation Of Press Releasebse
08 Dec, 03:25 pmCaplin Point Laboratories Limited has informed the Exchange regarding receipt of USFDA approval by its Subsidiary Caplin Steriles Limited for Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL) Single-dose Infusion Bags.nse
14 Nov, 05:23 pmCaplin Point Laboratories Limited has informed the Exchange about Acquisition of land by Subsidiarynse
12 Nov, 06:52 pmCaplin Point Laboratories Limited has informed the Exchange about Transcriptnse
12 Nov, 06:49 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
06 Nov, 06:36 pmCaplin Point Laboratories Limited has informed the Exchange about Link of Recordingnse
06 Nov, 06:29 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
05 Nov, 04:37 pmCaplin Point Laboratories Limited has informed the Exchange regarding Appointment of Mr Mr. Ashok Partheeban, Vivek Partheeban & K C John as Directors of the company w.e.f. November 05, 2025.nse
05 Nov, 04:33 pmCaplin Point Laboratories Limited has informed the Exchange regarding Resignation of Mr Vivek Partheeban as Chief Operating Officer of the company w.e.f. November 05, 2025.nse
05 Nov, 04:26 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Change in Managementbse
05 Nov, 04:23 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Change in Managementbse
05 Nov, 01:49 pmCaplin Point Laboratories Ltd - 524742 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025bse
05 Nov, 01:45 pmCaplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
05 Nov, 01:41 pmCaplin Point Laboratories Ltd - 524742 - Board Meeting Outcome for Outcome Of The Board Meetingbse
29 Oct, 07:12 pmCaplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30, 2025bse
29 Oct, 06:33 pmCaplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Considering And Approving, Inter-Alia, The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30, 2025bse
23 Oct, 02:51 pmCaplin Point Laboratories Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "CAPLIN STERILES GETS USFDA APPROVAL FOR NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION, INFUSION BAGS".nse
23 Oct, 02:49 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
29 Sept, 03:08 pmCaplin Point Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
22 Sept, 05:10 pmCaplin Point Laboratories Limited has informed the Exchange about change in Managementnse
22 Sept, 05:04 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Change in Managementbse
03 Sept, 02:01 pmCaplin Point Laboratories Limited has informed the Exchange regarding a press release dated September 03, 2025, titled "Press Release - Receipt of USFDA approval".nse
03 Sept, 01:58 pmCaplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse